Chapters

Transcript

Video

Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Name: Phase 2 Study of the Oral Hypoxia-Inducible Factor 2a (HIF-2a) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Uploaded: 2021-02-19T00:00:00+00:00
Description: Kidney Cancer Research: HIF-2a drug combination shows promise in previously treated patients with clear cell renal cell carcinoma. Preliminary results presented by Toni Chouieiri, MD at ASCO #GU21

Kidney Cancer Research: HIF-2a drug combination shows promise in previously treated patients with clear cell renal cell carcinoma. Preliminary results presented by Toni Chouieiri, MD at ASCO #GU21 abstract 272

Published

February 19, 2021

Created by

Related Presenters

Toni Choueiri, MD

Medical Oncology

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair ...

View Full Profile

Related Videos

Video

ASCO 2023: Bladder Cancer Highlights Presented By Charlene Mantia, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2023.

Video

ASCO 2023: Prostate Cancer Highlights Presented By Jacob Berchuck, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2023.

Video

ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2023.

Video

ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD

Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.

Video

ASCO 2023: Prostate Cancer Research Presented by Praful Ravi, MB BCHIR, MRCP

ICECAP collaboration was the largest study looking at the prognostic value of PSA nadir in localized prostate cancer, finding a PSA level of less than 0.1 could provide an early prognosis signal.

Video

ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD

Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.

Video

ASCO 2023: Treating NUT Carcinoma Research Presented by Jia Luo, MD

Dana-Farber's Jia Luo, MD, details on findings from the NUT Carcinoma Registry on initial chemotherapy for locally advanced and metastatic disease.

Video

ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD

We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.

Video

ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD

Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.